• Orum Therapeutics

  Participated · Series B · Jul 2019

  Orum Therapeutics is focused on building out its in-house DAC (DAC 플랫폼) technology, which it positions as the foundation for a new generation of therapeutic products. According to the fundraising announcement, the company intends to use freshly secured capital to speed up R&D and overall platform sophistication. The 1,450 억원 injection, raised through the issuance of convertible preferred shares, considerably strengthens Orum Therapeutics’ balance sheet and provides resources for continued scientific work. Management emphasized that the immediate priority is further optimization of the DAC platform, suggesting expanded pre-clinical and clinical efforts could follow. No specific operating metrics such as revenue or pipeline stage counts were disclosed, but the size of the round signals strong outside confidence in the firm’s progress to date. The company’s future plans center on translating its platform advancements into differentiated therapeutic candidates.

No current team members are available.